Abbott, Cincinnati Children's Hospital to develop urine-based diagnostic assay for kidney injury, disease

By Lisa Kerner

Charlotte, N.C., June 27 - Abbott said it signed an exclusive agreement with Cincinnati Children's Hospital to develop a urine-based diagnostic assay to detect kidney injury and disease using the protein neutrophil gelatinase-associated lipocalin (NGAL).

The NGAL biomarker has assisted physicians in rapidly diagnosing acute kidney failure in hours compared to current tests that may take up to several days, the company said.

"We are excited to begin our work in developing a test that may help clinicians address kidney failure much earlier and with greater precision," William E. Brown, Abbott's vice president, diagnostic assays and systems development, said in a company news release.

In previously published studies, concentrations of NGAL were raised in the urine and serum of children with acute kidney failure after undergoing cardiopulmonary bypass surgery and NGAL was useful in predicting kidney failure in patients following kidney transplantation.

Abbott develops pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.